Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22098331 | 1.00 | CYP4F2 (0.36) | CYP4F2CYP4A11PER2CRY1CRY2 | |
| SCHEMBL14295197 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL4566681 | 0.87 | CYP4F2 (0.35) | CYP4F2CYP4A11KDM4EALDH1A1MEN1 | |
| SCHEMBL15867020 | 0.80 | ALDH1A1 (0.47) | KDM4EALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL4713084 | 0.79 | CYP4F2 (0.33) | CYP4F2CYP4A11KDM4EALDH1A1MEN1 | |
| SCHEMBL14500716 | 0.79 | CYP4F2 (0.33) | CYP4F2CYP4A11KDM4EALDH1A1MEN1 | |
| SCHEMBL4713086 | 0.79 | CYP4F2 (0.33) | CYP4F2CYP4A11KDM4EALDH1A1MEN1 | |
| SCHEMBL762461 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL12385811 | 0.77 | JAK2 (0.32) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL12548932 | 0.76 | CYP4F2 (0.39) | CYP4F2CYP4A11KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539344-B1 | HALOGEN OR CYANO SUBSTITUTED THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | CYP4F2 103/4885CYP4A11 343/4885PER2 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.